RET and non-small cell lung carcinoma: LIBRETTO-001 trial reported that the median progression-free survival (PFS) in RET fusion-positive NSCLC patients treated with selpercatinib was 17 months, and the overall response rate (ORR) in untreated and pretreated patients were 64% [95% confidence interval (CI), 54%−73%] and 85% (95% CI, 70%−94%), respectively (6).